A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates.  Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study compared to the benchmark survival rate of 10%.  […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!